The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.
Complex chronic comorbidities of COPD
Open accessAbstract
Chronic obstructive pulmonary disease (COPD) is defined by fixed airflow limitation associated with an abnormal pulmonary and systemic inflammatory response of the lungs to cigarette smoke. The systemic inflammation induced by smoking may also cause chronic heart failure, metabolic syndrome and other chronic diseases, which may contribute to the clinical manifestations and natural history of COPD. Thus COPD can no longer be considered a disease only of the lungs, as it is often associated with a wide variety of systemic consequences. A better understanding of the origin and consequences of systemic inflammation, and of potential therapies, will most likely lead to better care of patients with COPD. Medical textbooks and clinical guidelines still largely ignore the fact that COPD seldom occurs in isolation. As the diagnosis and assessment of severity of COPD may be greatly affected by the presence of comorbid conditions, the current authors believe that lung function measurement, noninvasive assessment of cardiovascular and metabolic functions, and circulating inflammatory markers (e.g. C-reactive protein) might help to better characterise these patients. Similarly, preventive and therapeutic interventions should address the patient in their complexity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
Harrison's Principles of Internal Medicine.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-499_2 · Cited by 12,528
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Self-citationCelli, B. R., MacNee, W., Agustí, A. G. N., Anzueto, A. R., Berg, B., Buist, A. S., Calverley, P. M., Chavannes, N. H., Dillard, T. A., Fahy, B. F., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,405
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
CALVERLEY, P. M. A., Anderson, J. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., Jones, P., Yates, J., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,234
Research works printed but not linked: 8
- Fabbri LM, Rabe KF. Complexity of patients with multiple chronic diseases. Proceedings of an ERS Research Seminar (Rome, February 11–12, 2007). www.ersnet.org/ers/lr/browse/default.aspx?id_dossier = 67422 Date last accessed: October 31, 2007.
- 2005, Exp Lung Res, 31, 72
- 2007, Curr Opin Pulm Med, 13, 114
- 1996, Diabetes Metab, 22, 37
- 2000, Am J Respir Crit Care Med, 161, A583
- 2006, Cardiovasc Res, 3, e333
- 2005, Cochrane Database Syst Rev, 3, CD005374
- 2007, Curr Opin Pulm Med, 13, 90
Cited by
Sorted by citations
Items 101–200 of 655
Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics
Brassington, K., Selemidis, S., Bozinovski, S., & Vlahos, R. (2022) · Clinical Science · doi:10.1042/cs20210835 · Cited by 72
Lee, C. T., Mao, I., Lin, C., Lin, S., & Hsieh, M. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12147 · Cited by 63
Minas, M., Κostikas, Κ., Papaioannou, A. Ι., Mystridou, P., Karetsi, E., Georgoulias, P., Liakos, N., Pournaras, S., & Gourgoulianis, K. I. (2011) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2011.619600 · Cited by 63
“flammatory syndrome” (41) and may be at risk for the development of CVD and type-2 diabetes.”
BackgroundChetty, U., McLean, G., Morrison, D., Agur, K., Guthrie, B., & Mercer, S. W. (2017) · British Journal of General Practice · doi:10.3399/bjgp17x690605 · Cited by 62
Stockley, R. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902868971 · Cited by 61
Causes of Death Associated With Prolonged TV Viewing
Keadle, S. K., Moore, S. C., Sampson, J. N., Xiao, Q., Albanes, D., & Matthews, C. E. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.05.023 · Cited by 62
Natural history of COPD: gaps and opportunities
Agustí, A. G. N., & Celli, B. R. (2017) · ERJ Open Research · doi:10.1183/23120541.00117-2017 · Cited by 64
Chiang, Y. ‐., & Lin, H. ‐. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04009.x · Cited by 60
Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease
Roca, M., Verduri, A., Corbetta, L., Clini, E. M., Fabbri, L. M., & Beghé, B. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12064 · Cited by 59
Rennard, S. I., Thomashow, B. M., Crapo, J. D., Yawn, B. P., McIvor, A., Cerreta, S., Walsh, J. N., & Mannino, D. M. (2013) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2013.801309 · Cited by 59
McNicholas, W. T. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.117 · Cited by 58
“In COPD, mechanisms include hypoxia, systemic inflammation and oxidative stress, in addition to sympathetic excitation and vascular dysfunction (35).”
BackgroundKopf, S., Kumar, V., Κender, Ζ., Han, Z., Fleming, T., Herzig, S., & Nawroth, P. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.765201 · Cited by 60
Obstructive sleep apnea in chronic obstructive pulmonary disease patients
Lee, R., & McNicholas, W. T. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32834317bb · Cited by 57
Margrétardóttir, Ó. B., Thorleifsson, S. J., Guðmundsson, G., Ólafsson, Í., Benediktsdóttir, B., Janson, C., Buist, A. S., & Gíslason, Þ. (2009) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550903049157 · Cited by 57
“CRP is increased in all the major comorbidities of COPD like cardiovascular diseases, hypertension and diabetes (13, 14) but how this low-grade systemic inflammation accelerates progression of COPD is not well understood (26).”
BackgroundAcute kidney injury in stable COPD and at exacerbation
Barakat, M., McDonald, H. I., Collier, T. J., Smeeth, L. L., Nitsch, D., & Quint, J. K. (2015) · International Journal of COPD · doi:10.2147/copd.s88759 · Cited by 60
Nonpharmacological treatment and relief of symptoms in COPD: Table 1—
Clini, E. M., & Ambrosino, N. (2008) · European Respiratory Journal · doi:10.1183/09031936.00134007 · Cited by 55
Chen, S.-J., Liao, W.-C., Huang, K., Lin, C., Tsai, W., Kung, P., Chang, K., & Kao, C. (2015) · QJM · doi:10.1093/qjmed/hcv012 · Cited by 55
“Patients with chronic obstructive pulmonary disease and allied conditions (COPD) are frequently associated with an increased risk of comorbidities, such as cardiovascular diseases, peptic ulcer/gastroesophageal reflux disease, metabolic syndrome, diabetes, lung cancer and osteoporosis.(1,2) Osteoporosis is more common…”
BackgroundWater-based exercise training for chronic obstructive pulmonary disease
McNamara, R. J., McKeough, Z. J., McKenzie, D. K., & Alison, J. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008290.pub2 · Cited by 53
Park, S. K., & Larson, J. L. (2013) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0000000000000096 · Cited by 57
GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists
Agustí, A. G. N., Böhm, M., Celli, B. R., Criner, G. J., García‐Álvarez, A., Martínez, F. J., Sin, D. D., & Vogelmeier, C. F. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02217-0 · Cited by 53
“Arterial hypertension is the most frequently occurring comorbidity in COPD and may have implications for prognosis [38, 39].”
BackgroundLiao, W. ‐., Lin, C., Chang, S., Tu, C. ‐., & Kao, C. ‐. (2014) · European Journal of Neurology · doi:10.1111/ene.12573 · Cited by 53
“The most frequently reported comorbidities are cardiovascular diseases, including ischaemic heart disease, atrial fibrillation and hypertension, as well as peptic ulcer, osteoporosis, metabolic syndrome, diabetes and lung cancer [3,4].”
BackgroundChronic Obstructive Pulmonary Disease with Lung Cancer and/or Cardiovascular Disease
Rodriguez‐Roisin, R., & Soriano, J. B. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200807-075th · Cited by 54
Gene promoter methylation is associated with lung function in the elderly: The normative aging study
Lepeule, J., Baccarelli, A., Tarantini, L., Motta, V., Cantone, L., Litonjua, A. A., Sparrow, D., Vokonas, P., & Schwartz, J. D. (2012) · Epigenetics · doi:10.4161/epi.7.3.19216 · Cited by 53
“Similar associations were found in the secondary analyses looking at individual positions within each gene (Table S4), but only some of the positions showed significant associations: mortality,(13-15) though the causal pathways are poorly understood.(13,16) Faster lung function decline has been associated with increas…”
ResultChronic obstructive pulmonary disease (COPD) and old age?
Jarad, N. A. (2011) · Chronic Respiratory Disease · doi:10.1177/1479972311407218 · Cited by 52
Park, Y. B., Rhee, C. K., Yoon, H. K., Oh, Y., Lim, S. Y., Lee, J. H., Yoo, K. H., & Ahn, J. H. (2018) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2018.0029 · Cited by 52
Prognostic assessment in COPD without lung function: the B-AE-D indices
Boeck, L., Soriano, J. B., Brusse-Keizer, M. G. J., Blasi, F., Κostikas, Κ., Boersma, W. G., Milenkovic, B. A., Louis, R. E., Lacoma, A., Djamin, R. S., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01485-2015 · Cited by 51
The recent advances of phenotypes in acute exacerbations of COPD
Zhou, A., Zhou, Z., Zhao, Y., & Chen, P. (2017) · International Journal of COPD · doi:10.2147/copd.s128604 · Cited by 50
Romme, E. A., Murchison, J. T., Edwards, L. D., van Beek, E. J. R., Murchison, D. M., Rutten, E. P. A., Smeenk, F. W. J. M., Williams, M. C., Wouters, E. F. �., MacNee, W., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1873 · Cited by 49
Bhandari, N. J., Jain, T., Marolda, C., & ZuWallack, R. (2013) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e31828254d4 · Cited by 49
Chronic obstructive pulmonary disease and cancer risk: A Danish nationwide cohort study
Kornum, J. B., Sværke, C., Thomsen, R. W., Lange, P., & Sørensen, H. T. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2011.12.009 · Cited by 48
Cruz, F. F., Antunes, M. A., Abreu, S. C., Fujisaki, L. C., Silva, J. D., Xisto, D. G., Maron‐Gutierrez, T., Ornellas, D. S., Sá, V. K., Rocha, N. N., et al. (2012) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2012.01.002 · Cited by 48
Treatment of Chronic Obstructive Pulmonary Disease and Its Comorbidities
Luppi, F., Franco, F., Beghé, B., & Fabbri, L. M. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-101th · Cited by 48
Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD
Pépin, J., Cockcroft, J. R., Midwinter, D., Sharma, S., Rubin, D. B., & Andreas, S. (2014) · CHEST Journal · doi:10.1378/chest.13-2859 · Cited by 46
Hornikx, M., Remoortel, H. V., Demeyer, H., Camillo, C. A., Decramer, M., Janssens, W., & Troosters, T. (2013) · BioMed Research International · doi:10.1155/2013/146148 · Cited by 50
“The pulmonary component of the disease is characterized by airflow limitation and chronic inflammation and typically gives rise to symptoms of cough, sputum production, and dyspnea [2].”
BackgroundOliveira, M. V., Abreu, S. C., Padilha, G. A., Rocha, N. N., Maia, L. A., Takiya, C. M., Xisto, D. G., Suki, B., Silva, P. L., & Rocco, P. R. M. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00457 · Cited by 46
Association between lung function, hypertension and blood pressure medication
Schnabel, E., Nowak, D., Brasche, S., Wichmann, H. ‐., & Heinrich, J. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2010.12.023 · Cited by 45
Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease
Kayongo, A., Robertson, N. M., Siddharthan, T., Ntayi, M. L., Ndawula, J. C., Sande, O. J., Bagaya, B. S., Kirenga, B., Mayanja‐Kizza, H., Joloba, M. L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1085551 · Cited by 50
“Nat Rev Microbiol (2017) 15(5):259– 70.”
BackgroundInfluentialImpact of comorbidities in COPD clinical control criteria. The CLAVE study
Almagro, P., Soler‐Cataluña, J. J., Huerta, A. H., González-Segura, D., Cosío, B. G., & on behalf of the CLAVE Study Investigators (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02758-0 · Cited by 44
“Comorbidities negatively impact the prognosis, symptoms, and quality of life in COPD patients, but to our knowledge, their impact on clinical control criteria has only been partially explored [16, 19, 20, 22].”
BackgroundHashimoto, N., Matsuzaki, A., Okada, Y., Imai, N., Iwano, S., Wakai, K., Imaizumi, K., Yokoi, K., & Hasegawa, Y. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-14 · Cited by 44
“However, because older patients with COPD are often known to have much lower pulmonary function as well as other comorbidities [7,8], whether or not the decision-making process for therapeutic management of lung cancer patients might be independently affected by the coexistence and severity of COPD remains elusive.”
BackgroundChicken or egg: physical activity in COPD revisited
Polkey, M. I., & Rabe, K. F. (2009) · European Respiratory Journal · doi:10.1183/09031936.00176808 · Cited by 45
Koo, H., Kang, H. K., Song, P., Park, H. K., Lee, S.-S., & Jung, H. (2017) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.80.3.304 · Cited by 43
Zhang, P., Chen, B., Lou, H., Zhu, Y., Chen, P., Dong, Z., Zhu, X., Li, T., & Lou, P. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01780-4 · Cited by 43
“Hypertension is the most frequently occurring comorbidity, while diabetes also damages lung function [38].”
BackgroundDivo, M. J., Marín, J. M., Casanova, C., López, C. C., Pinto-Plata, V., Marín‐Oto, M., Polverino, F., de-Torres, J. P., Billheimer, D. D., Celli, B. R., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02191-7 · Cited by 46
“COPD rarely presents as the only disease affecting a patient, as more than 80% of COPD patients have one or more comorbidity [5].”
BackgroundStatins Decrease Lung Inflammation in Mice by Upregulating Tetraspanin CD9 in Macrophages
Jin, Y., Tachibana, I., Takeda, Y., He, P., Kang, S., Suzuki, M., Kuhara, H., Tetsumoto, S., Tsujino, K., Minami, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073706 · Cited by 42
“emphysema and its comorbidities may have a common pathophysiologic mechanism [4].”
Matera, M. G., Martuscelli, E., & Cazzola, M. (2009) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2009.10.001 · Cited by 42
Energy expenditure and substrate oxidation during and after eccentric cycling
Peñailillo, L., Blazevich, A. J., & Nosaka, K. (2014) · European Journal of Applied Physiology · doi:10.1007/s00421-013-2816-3 · Cited by 41
“The lack of glucose intolerance is important because it is known that elderly and both cardiac and respiratory disease patients have a higher risk of developing insulin resistance and dyslipidaemia (Fabbri et al. 2008), and muscle damaging exercises may induce or exacerbate transient glucose intolerance.”
BackgroundA practice-based analysis of combinations of diseases in patients aged 65 or older in primary care
Boeckxstaens, P., Peersman, W., Goubin, G., Ghali, S., Maeseneer, J. D., Brusselle, G., & Sutter, A. D. (2014) · BMC Family Practice · doi:10.1186/1471-2296-15-159 · Cited by 41
“and to engage in the development of randomized clinical trials or guidelines on patients with these combinations of diseases [8,9].”
Update in Chronic Obstructive Pulmonary Disease 2007
MacNee, W. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200801-167up · Cited by 41
“COPD is associated with many comorbidities (102).”
Risk factors and pathophysiology of chronic obstructive pulmonary disease (COPD).
Brashier, B. B., & Kodgule, R. (2012) · PubMed · Cited by 42
Luo, C.-S., Chi, C.-C., Fang, Y.-A., Liu, J.-C., & Lee, K.-Y. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001155 · Cited by 39
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 55
Wu, K., Lu, L., Chen, Y., Peng, J., Wu, X., Tang, G., Ma, T., Cheng, J., Ran, P., & Zhou, Y. (2024) · Pulmonology · doi:10.1080/25310429.2024.2438553 · Cited by 39
Heidari, B. (2012) · Europe PMC (PubMed Central) · Cited by 39
Comorbidity in chronic obstructive pulmonary disease. Related to disease severity?
Echave-Sustaeta, J. M., Casanova, L. C., Cosío, B. G., Soler‐Cataluña, J. J., Luján, R. G., & Ribera, X. (2014) · International Journal of COPD · doi:10.2147/copd.s71849 · Cited by 39
When kidneys and lungs suffer together
Sorino, C., Scichilone, N., Pedone, C., Negri, S., Visca, D., & Spanevello, A. (2018) · Journal of Nephrology · doi:10.1007/s40620-018-00563-1 · Cited by 39
Yohannes, A. M., Raue, P. J., Kanellopoulos, D., McGovern, A. R., Sirey, J. A., Kiosses, D. N., Banerjee, S., Seirup, J. K., Novitch, R. S., & Alexopoulos, G. S. (2015) · CHEST Journal · doi:10.1378/chest.15-0529 · Cited by 39
“Unlike osteoporosis, in which the most common cause of mortality is fractures,(26,27) mortality related to COPD is multifactorial and includes exacerbations of COPD, respiratory infections, and worsening of other medical illnesses that are commonly comorbid with COPD, including coronary artery disease, heart failure,…”
BackgroundDeterminants of exercise capacity in obese and non-obese COPD patients
Rodriguez, D. A., García‐Aymerich, J., Valera, J. L., Sauleda, J., Togores, B., Gáldiz, J. B., Gea, J., Orozco‐Levi, M., Ferrer, A., Gómez, F. P., et al. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.02.004 · Cited by 42
Yoon, H. K., Park, Y. B., Rhee, C. K., Lee, J. H., & Oh, Y. (2017) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2017.80.3.230 · Cited by 38
Huang, Y. L., Lai, C., Wang, Y., Wang, C., Wang, J., Wang, H., Yu, C., & Chen, L. (2017) · International Journal of COPD · doi:10.2147/copd.s145913 · Cited by 38
Disability in COPD and its relationship to clinical and patient-reported outcomes
Braido, F., Baiardini, I., Menoni, S., Bagnasco, A., Balbi, F., Bocchibianchi, S., Balestracci, S., Piroddi, M. G., & Canonica, G. W. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.563285 · Cited by 39
Reduced nuclear factor-κB repressing factor: a link toward systemic inflammation in COPD
Lee, K., Ho, S., Chan, Y., Wang, C., Huang, C., Liu, W., Lin, S., Lo, Y.-L., Chang, Y.-L., Kuo, L.-W., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00146811 · Cited by 40
John, M., Cockcroft, J., McKeever, T. M., Coward, W. R., Shale, D. J., Johnson, S. R., Thornton, J., Harrison, T. W., Knox, A. J., & Bolton, C. E. (2015) · International Journal of COPD · doi:10.2147/copd.s76061 · Cited by 37
Managing Older Patients with Coexistent Asthma and Chronic Obstructive Pulmonary Disease
McDonald, V. M., Higgins, I., & Gibson, P. G. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0042-z · Cited by 38
“There is an immediate need to improve the approach to diagnosis and management in this population [1, 11–15].”
BackgroundInfluentialComorbidity of mental and physical disorders
(2014) · Key Issues in Mental Health · doi:10.1159/isbn.978-3-318-02604-7 · Cited by 37
Systematic review of anaemia and inflammatory markers in chronic obstructive pulmonary disease
Hoepers, A. T. D. C., Pizzichini, M. M. M., & Fröde, T. S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12357 · Cited by 36
New Predictor of Atherosclerosis in Subjects With COPD: Atherogenic Indices
Günay, S., Sarıaydın, M., & Acay, A. (2016) · Respiratory Care · doi:10.4187/respcare.04796 · Cited by 36
Obesity and metabolic syndrome in COPD: Is exercise the answer?
James, B., Jones, A., Trethewey, R. E., & Evans, R. A. (2017) · Chronic Respiratory Disease · doi:10.1177/1479972317736294 · Cited by 44
“This association likely relates to several pathophysiological mechanisms, including systemic inflammation, physical inactivity and oxidative stress.(26,29) International COPD guidelines recommend ‘the proactive identification and treatment of comorbidities’,(30) yet often this is routinely performed in clinical practi…”
BackgroundKim, V., Kretschman, D. M., Sternberg, A. L., DeCamp, M. M., & Criner, G. J. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0538oc · Cited by 36
“The abnormal local inflammatory response to cigarette smoke leads to airflow obstruction and also results in systemic inflammation, characterized by increased levels of IL-6, IL-8, tumor necrosis factor (TNF)-a, and C-reactive protein (3); this systemic inflammation is believed to be responsible for accelerated bone l…”
BackgroundToraldo, D. M., & Conte, L. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3875 · Cited by 36
“COPD can no longer be considered as a disease that only involves the lungs, but rather a disease associated with a systemic inflammatory component, which links the disease with other extrapulmonary co-morbidities, such as cardiovascular disorders, skeletal muscle alterations, diabetes, osteoporosis, anxiety, and depre…”
BackgroundRelationship between heart failure and the risk of acute exacerbation of COPD
Axson, E. L., Bottle, A., Cowie, M., & Quint, J. K. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-216390 · Cited by 37
“30 31 Higher comorbidity burden is associated with increased risk of death in patients with COPD 32 and increased systemic inflammation.”
Chung, K. S., Park, H. J., Leem, A. Y., Lee, S. H., Song, J. H., Park, M. S., Kim, Y. S., Kim, S. I., & Chang, J. (2015) · International Journal of COPD · doi:10.2147/copd.s85767 · Cited by 35
“Osteoporosis is a major comorbidity in COPD.(7) It is also associated with poor health status and prognosis.”
BackgroundInfluentialPark, J., Kim, T., Joo, H., Lee, J. S., Lee, S., & Oh, Y. (2012) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2013.5.1.16 · Cited by 33
Carreiro, A., Santos, J. V. D., & Rodrigues, F. (2013) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppneu.2012.12.004 · Cited by 36
Guerra, B., Haile, S. R., Lamprecht, B., Ramírez, A. S., Martínez‐Camblor, P., Kaiser, B., Alfageme, I., Almagro, P., Casanova, C., Esteban, C., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1013-y · Cited by 35
“Also, prognostic scores for all-cause mortality are particularly attractive for multimorbid patients such as COPD patients, where cardiovascular disease, diabetes, renal disease, and lung cancer, among other conditions, also contribute to mortality [68, 69].”
BackgroundAssociation between Airflow Obstruction and the Metabolic Syndrome or Its Components in Japanese Men
Funakoshi, Y., Omori, H., 修一, 三., Marubayashi, T., & Katoh, T. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3882 · Cited by 34
“Individuals with COPD show evidence of systemic inflammation including coronary artery disease, diabetes, hypertension, osteoporosis, and muscle weakness (1, 4-9).”
BackgroundComorbidity of Heart Failure and Chronic Obstructive Pulmonary Disease: More than Coincidence
Güder, G., & Rutten, F. H. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0212-x · Cited by 34
COPD and microalbuminuria: a 12-year follow-up study
Romundstad, S., Naustdal, T., Romundstad, P., Sorger, H., & Langhammer, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00160213 · Cited by 33
Dugac, A. V., Ružić, A., Samaržija, M., Badovinac, S., Kehler, T., & Jakopović, M. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.11.017 · Cited by 33
Almagro, P., López, F., Cabrera, F. J., Portillo, J., Fernández‐Ruiz, M., Zubillaga, E., Díez‐Manglano, J., Román, P., Murcia‐Zaragoza, J., Boixeda, R., et al. (2012) · Revista Clínica Española · doi:10.1016/j.rce.2012.02.014 · Cited by 33
Sympathetic Activation is Associated with Exercise Limitation in COPD
Haarmann, H., Folle, J., Nguyen, X. P., Herrmann, P., Heusser, K., Hasenfuss, G. P., Andreas, S., & Raupach, T. (2016) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2015.1136272 · Cited by 32
“Although COPD affects primarily the lungs, systemic effects of COPD significantly contribute to its severity and overall mortality (7, 8).”
BackgroundUnmet needs in the management of exacerbations of chronic obstructive pulmonary disease
Waeijen-Smit, K., Houben‐Wilke, S., DiGiandomenico, A., Gehrmann, U., & Franssen, F. M. E. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02612-9 · Cited by 33
Schünemann, H. J., Woodhead, M. A., Anzueto, A., Buist, A. S., MacNee, W., Rabe, K. F., & Heffner, J. E. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201208-053st · Cited by 32
Yasar, Z. A., Büyükşirin, M., Üçsular, F. D., Karğı, A., Erdem, F., Talay, F., & Kurt, Ö. K. (2015) · PubMed · Cited by 32
Zhang, X., Cai, X., Shi, X., Zheng, Z., Zhang, A., Guo, J., & Fang, Y. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150735 · Cited by 33
“Researchers have shown that COPD has a potential influence on cognitive impairment [8–12]; however, the results have been inconsistent [13–16].”
Smooth Bayesian network model for the prediction of future high-cost patients with COPD
Lin, S., Zhang, Q., Chen, F. Y., Luo, L., Chen, L., & Zhang, W. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.03.017 · Cited by 32
COPD and the Solar System: Introducing the Chronic Obstructive Pulmonary Disease Comorbidome
Fabbri, L. M., Beghé, B., & Agustí, A. G. N. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201205-0906ed · Cited by 32
“, ischemic heart disease, chronic heart failure, arrhythmia, osteoporosis, and metabolic syndrome) (3, 4).”
BackgroundFirouzjahi, A., Monadi, M., Karimpoor, F., Heidari, B., Dankoob, Y., Hajian‐Tilaki, K., & Firozjaii, M. G. (2013) · Inflammation · doi:10.1007/s10753-013-9646-7 · Cited by 31
“Inflammatory process has a contributive role not only in the development of pulmonary small-airways obstructive disease, but it is also implicated in the evolution of disease process to extrapulmonary organs and overall morbidity and mortality [4, 5].”
BackgroundBartels, W., Adamson, S., Leung, L., Sin, D. D., & van Eeden, S. F. (2018) · International Journal of COPD · doi:10.2147/copd.s163250 · Cited by 31
“come because of many sharing risk factors and compounding effects on disease severity.(37,38) Cardiovascular comorbidities”
BackgroundMcNamara, R. J., McKeough, Z. J., McKenzie, D. K., & Alison, J. A. (2014) · Respirology · doi:10.1111/resp.12325 · Cited by 30
Real-World Clinical Data Identifies Gender-related Profiles in Chronic Obstructive Pulmonary Disease
Laitinen, T., Hodgson, U., Kupiainen, H., Tammilehto, L., Haahtela, T., Kilpeläinen, M., Lindqvist, A. E., & Kinnula, V. L. (2009) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550903051799 · Cited by 31
Ho, C., Chen, Y., Wang, J., & Liao, K. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013195 · Cited by 31
“The systemic effects of smoking and chronic systemic inflammation responses in patients with COPD contribute to the development of respiratory symptoms, functional impairment, and chronic comorbidities and include extrapulmonary cancers.(4) A previous study demonstrated that COPD was associated with an increased risk…”
BackgroundBoschetto, P., Fucili, A., Stendardo, M., Malagù, M., Parrinello, G., Casimirri, E., Potena, A., Ballerin, L., Fabbri, L. M., Ferrari, R., et al. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02264.x · Cited by 30
Yin, L., Lensmar, C., Ingelsson, E., & Bäck, M. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.140 · Cited by 30
“Chronic obstructive pulmonary disease (COPD) has been associated with an increased risk of cardiovascular disease, which has been suggested to relate to both similar risk factors and to similar pathophysiological mechanisms [1–4].”
BackgroundInhaled corticosteroids in chronic obstructive pulmonary disease: a pro–con perspective
Babu, K. S., Kastelik, J. A., & Morjaria, J. B. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12334 · Cited by 30
Rothnie, K., & Quint, J. K. (2016) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcw005 · Cited by 30
Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease
Doehner, W., Hæusler, K. G., Endres, M., Anker, S. D., MacNee, W., & Lainščak, M. (2011) · Respiratory Medicine · doi:10.1016/s0954-6111(11)70005-1 · Cited by 29
Chen, W., Lin, C.-W., Chen, Y.-Y., Chen, Y.-J., Liang, C.-Y., & Lin, M. (2015) · International Journal of COPD · doi:10.2147/copd.s85432 · Cited by 29
Rossi, A., Inciardi, R. M., Rossi, A., Temporelli, P. L., Lucci, D., Gonzini, L., Marchioli, R., Nicolosi, G. L., & Tavazzi, L. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.001 · Cited by 29
Hu, G., Zhou, Y., Wu, Y., Yu, Y., Liang, W., & Ran, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133160 · Cited by 29
“COPD patients have an increased prevalence of cancer, cardiovascular disease and depression compared with the general population[23].”
BackgroundLong-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease
Rennard, S. I., Flavin, S. K., Agarwal, P., Lo, K. H., & Barnathan, E. S. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.11.008 · Cited by 29
“In addition, extrapulmonary manifestations are common.(3,4) Smoking is a causative factor of COPD(5) and increases the risk for several types of cancer.”
Background
Metadata
- Authors
- Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2007-12-31
- Volume
- 31
- Issue
- 1
- Pages
- 204-212
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2165340553
- Cited by
- 660
- References
- 139
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 20 · 2023: 17 · 2022: 26 · 2021: 19 · 2020: 35 · 2019: 25 · 2018: 36 · 2017: 48 · 2016: 31 · 2015: 50 · 2014: 68 · 2013: 55 · 2012: 59
- FWCI
- 28.24
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- chronic obstructive pulmonary disease, comorbidities, systemic inflammation, chronic heart failure, metabolic syndrome, cigarette smoking, C-reactive protein, inflammatory markers, COPD severity assessment, cardiovascular function, COPD management
- MeSH terms
- Chronic Disease, Health Status, Humans, Inflammation, Lung, Models, Biological, Prognosis, Risk Factors, Smoking, Pulmonary Medicine, Comorbidity, Guidelines as Topic, Pulmonary Disease, Chronic Obstructive, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
